Michael Buchert

Has grant

Scientific Laboratory Head

Olivia Newton-John Cancer Research Institute
Country flagAustralia

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Evaluation of circulating immune cell subtypes for the early detection of stomach cancer

Open Date: 2022-01-01

Close Date: 2022-12-01

Grant: Close

Exploiting the cross talk between Tuft cells and group 2 innate lymphoid cells for tissue homeostasis and disease

Open Date: 2018-01-01

Close Date: 2020-12-01

Grant: Close

The FGFR family as drivers and biomarkers of regorafenib response in gastric cancer

Open Date: 2017-01-01

Close Date: 2019-12-01

Grant: Close

Role of MACROD2 Loss in DNA Repair, Chromosomal Instability and Development of Colorectal Cancer: Clinical and Therapeutic Implications

Open Date: 2015-01-01

Close Date: 2017-12-01

Grant: Close

Targeting colorectal cancer with Jak kinase inhibitors

Open Date: 2014-01-01

Close Date: 2016-01-01

Articles (12)

Minor splicing is an under-appreciated splicing system required for the correct expression of ~700 genes in the human genome. This small subset of genes (0.35%) harbours introns containing non-canonical splicing sequences that are recognised uniquely by the minor spliceosome and cannot be processed by the major spliceosome. Using in vivo zebrafish and mouse cancer models, we show that heterozygous expression of Rnpc3 , encoding a unique protein component of the minor spliceosome, restricts the growth and survival of liver, lung and gastric tumours without impacting healthy cells. RNPC3 knockdown in human lung cancer-derived A549 cells also impairs cell proliferation and RNA-seq analysis reveals a robust and selective disruption to minor intron splicing and transcription-wide effects on gene expression. We further demonstrate that these perturbations are accompanied by DNA replication stress, DNA damage, accumulation of TP53 protein and activation of a Tp53-dependent transcriptional program that induces cell cycle arrest and apoptosis. Together our data reveal a vulnerability of cancer cells to minor splicing inhibition that restricts tumour growth.

Year:

2025

Year:

2025

Fusobacterium nucleatum is an oncobacterium capable of promoting the growth and chemotherapy resistance of colonised tumours. Although F. nucleatum is usually susceptible to a range of antibiotics, these have been associated with worse outcomes when administered with anti-neoplastic chemotherapy. Bacteriophages are viewed as natural alternatives to antibiotics that provide bacterial-specific targeting. In this study, we demonstrated that gastric tumour tissues and cells expressed Gal-GalNac molecules that facilitate binding of the fap2 receptor on F. nucleatum, leading to increased cancer cell proliferation and migratory potential. We then employed an F. nucleatum specific bacteriophage, FNU1, to limit the effects of this oncobacteria in colon cancer and gastric cancer cell models. We demonstrated that FNU1 was able to negate the F. nucleatum-dependent growth stimulatory effects, migratory ability, induction of reactive oxygen species, and autophagy in these cell lines. F. nucleatum also inhibited apoptosis in co-cultures with colon and gastric cancer cells, and FNU1 acted synergistically with the chemotherapy agents 5-fluorouracil and oxaliplatin to induce apoptosis in these models. Treatments with bacteriophage FNU1, therefore, have the potential to augment existing cancer therapy, and further testing in animal models is warranted.

Year:

2025

Autophagy-related genes have been closely associated with intestinal homeostasis. BECLIN1 is a component of Class III phosphatidylinositol 3-kinase complexes that orchestrate autophagy initiation and endocytic trafficking. Here we show intestinal epithelium-specific BECLIN1 deletion in adult mice leads to rapid fatal enteritis with compromised gut barrier integrity, highlighting its intrinsic critical role in gut maintenance. BECLIN1-deficient intestinal epithelial cells exhibit extensive apoptosis, impaired autophagy, and stressed endoplasmic reticulum and mitochondria. Remaining absorptive enterocytes and secretory cells display morphological abnormalities. Deletion of the autophagy regulator, ATG7, fails to elicit similar effects, suggesting additional novel autophagy-independent functions of BECLIN1 distinct from ATG7. Indeed, organoids derived from BECLIN1 KO mice show E-CADHERIN mislocalisation associated with abnormalities in the endocytic trafficking pathway. This provides a mechanism linking endocytic trafficking mediated by BECLIN1 and loss of intestinal barrier integrity. Our findings establish an indispensable role of BECLIN1 in maintaining mammalian intestinal homeostasis and uncover its involvement in endocytic trafficking in this process. Hence, this study has important implications for our understanding of intestinal pathophysiology.

Year:

2024

Year:

2024

Year:

2024

Doublecortin-like kinase 1 (DCLK1) is a proposed driver of gastric cancer (GC) that phosphorylates serine and threonine residues. Here, we showed that the kinase activity of DCLK1 orchestrated cancer cell–intrinsic and–extrinsic processes that led to pro-invasive and pro-metastatic reprogramming of GC cells. Inhibition of the kinase activity of DCLK1 reduced the growth of subcutaneous xenograft tumors formed from MKN1 human gastric carcinoma cells in mice and decreased the abundance of the stromal markers α-Sma, vimentin, and collagen. Similar effects were seen in mice with xenograft tumors formed from MKN1 cells expressing a kinase-inactive DCLK1 mutant (MKN1 D511N ). MKN1 D511N cells also had reduced in vitro migratory potential and stemness compared with control cells. Mice orthotopically grafted with MKN1 cells overexpressing DCLK1 (MKN1 DCLK1 ) showed increased invasiveness and had a greater incidence of lung metastases compared with those grafted with control MKN1 cells. Mechanistically, we showed that the chemokine CXCL12 acted downstream of DCLK1 in cultured MKN1 cells and in mice subcutaneously implanted with gastric tumors formed by MKN1 DCLK1 cells. Moreover, inhibition of the kinase activity of DCLK1 or the expression of DCLK1 D511N reversed the pro-tumorigenic and pro-metastatic phenotype. Together, this study establishes DCLK1 as a broadly acting and potentially targetable promoter of GC.

Year:

2024

Although aberrant activation of the KRAS and PI3K pathway alongside TP53 mutations account for frequent aberrations in human gastric cancers, neither the sequence nor the individual contributions of these mutations have been clarified. Here, we establish an allelic series of mice to afford conditional expression in glandular epithelium of Kras G12D ; Pik3ca H1047R or Trp53 R172H and/or ablation of Pten or Trp53 . We find that Kras G12D ; Pik3ca H1047R is sufficient to induce adenomas, and that lesions progress to carcinoma when also harboring Pten -deletions. Additional challenge with either Trp53 loss- or gain-of-function alleles further accelerated tumor progression and triggered metastatic disease. While tumor-intrinsic STAT3 signaling in response to gp130 family cytokines remained as a gatekeeper for all stages of tumor development, metastatic progression required a mutant Trp53 -induced interleukin (IL)-11 to IL-6 dependency switch. Consistent with poorer survival of patients with high IL6 expression, we identify IL6/STAT3 signaling as a therapeutic vulnerability for TP53-mutant gastric cancer.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (12)

Sarah Ellis

Head, Microscopy Facility

Olivia Newton-John Cancer Research Institute

AUSTRALIA
View details

Daniele V. F. Tauriello

Assistant professor

Erasmus University Rotterdam

NETHERLANDS
View details

James Lee

The Francis Crick Institute

UNITED KINGDOM
View details

Marina H. Yakou

Olivia Newton-John Cancer Research Institute

AUSTRALIA
View details

Wei Shi

Professor

MONASH UNIVERSITY

AUSTRALIA
View details

isabelle lucet

Division Head

Walter and Eliza Hall Institute of Medical Research

AUSTRALIA
View details

Matthias Ernst

-

AUSTRALIA
View details

Yi-Ping Phoebe Chen

La Trobe University

AUSTRALIA
View details

John Mariadason

La Trobe University

AUSTRALIA
View details

Kieran Harvey

Group Leader

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Ryan O'Keefe

Olivia Newton-John Cancer Research Institute

AUSTRALIA
View details

Erinna Lee

La Trobe University

AUSTRALIA
View details